Previous findings from a clinical trial with Remygen[®] are discussed as part of a lecture on World Diabetes Day
Results from the initial dose escalation part of the phase I/II trial ReGenerate-1 with the study drug Remygen[®], which were announced in May this year, will be discussed by the trial's Sponsor and Principal Investigator Professor Per-Ola Carlsson during a web lecture to be held at Lund University in connection with World Diabetes Day on Saturday 14 November 2020.The results that will be discussed show that Remygen[®] improved the hormonal protection mechanisms that counteract hypoglycaemia. More specifically, the results show that during hypoglycaemia, the secretion of the hormones